vimarsana.com

Latest Breaking News On - Dermatological department - Page 1 : vimarsana.com

Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

/PRNewswire/ Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces initiation of the Phase III clinical trial of fatty acid synthase (FASN).

Hong kongAnn pharmacotherLeihong xiangJinzij wuSagimet biosciences incNational medical products administrationInstitute of dermatologyFudan universityAscletis pharma incPhysician of dermatological departmentDermatology division of chinese medical doctor associationHong kong stock exchangePrnewswire ascletis pharma incDrug evaluationInstitutional review boardHuashan hospital

Ascletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for Acne

Ascletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for Acne
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongLeihong xiangAnn pharmacotherJinzij wuFudan universityHong kong stock exchangeDrug administrationPhysician of dermatological departmentDermatology division of chinese medical doctor associationInstitute of dermatologyAscletis pharma incAscletis pharmaStudy resultsTopical clascoterone creamFacial acneTwo phase

Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne

To date, approximately 50% enrolled patients have completed 12-week treatment and all enrolled patients are expected to complete 12-week treatment by the end.

United statesHong kongLeihong xiangJinzij wuPhysician of dermatological departmentFudan universityHong kong stock exchangeInstitute of dermatologyDrug administrationDermatology division of chinese medical doctor associationAscletis pharma incAscletis pharmaGlobal assessmentChief physicianDermatological departmentHuashan hospital

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne

/PRNewswire/ Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC40 for moderate to.

Hong kongLeihong xiangJinzij wuMarket researchFudan universityDermatological departmentHong kong stock exchangeInstitute of dermatologyDermatology division of chinese medical doctor associationAscletis pharma incAscletis pharmaGlobal assessmentAllied market researchHuashan hospitalDermatology divisionChinese medical doctor

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne

/PRNewswire/ Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC40 for moderate to.

Hong kongLeihong xiangJinzij wuMarket researchFudan universityDermatological departmentHong kong stock exchangeInstitute of dermatologyDermatology division of chinese medical doctor associationAscletis pharma incAscletis pharmaGlobal assessmentAllied market researchHuashan hospitalDermatology divisionChinese medical doctor

vimarsana © 2020. All Rights Reserved.